Motivational Interviewing for Medication Adherence in Asthma
2018年2月9日 更新者:Simon Bacon、Hopital du Sacre-Coeur de Montreal
Impact of a Motivational Interviewing Intervention on Medication Adherence in Patients With Asthma
The high burden of asthma appears to be related to poor asthma control, which is associated with more frequent asthma symptoms, greater bronchodilator use and functional impairment, and worse pulmonary function.
Despite the availability of effective treatments, more than 58% of asthmatics are poorly controlled.
Daily adherence to inhaled corticosteroid (ICS) regimens is considered by experts to be one of the most important behavioral factors linked to achieving optimal asthma control.
However, there is a paucity of research on interventions specifically designed to improve ICS adherence among adult asthmatics.
The vast majority of intervention studies to date used atheoretical interventions to target behavior change, relying mainly upon educational approaches which have been criticised for "failing to translate knowledge into action."
This may be due to the fact that most education-based approaches do not specifically address or help patients overcome ambivalence about behavior change, which is necessary for ensuring daily adherence.
Motivational interviewing (MI) is a client-centred intervention that focuses on enhancing intrinsic motivation to change a particular behavior, and exploring and resolving ambivalence about behavior change.
Brief MI sessions (e.g., 1-5 x 15-30 minute sessions) have been shown to improve a variety of health behaviors (e.g., reduce alcohol consumption, improve dietary habits, increase exercise behaviour, and improve medication adherence) and health outcomes (reduce blood pressure, body mass index, and cholesterol levels).
However, no studies to date have assessed the efficacy of using MI to improve ICS adherence in asthmatics.
This study aims to assess the efficacy of using MI to improve daily medication (ICS) adherence in a sample of poorly controlled, non-adherent asthmatics.
It is hypothesized that patients randomized to the MI condition will exhibit significantly improved ICS adherence at 6 and 12-months post-intervention, independent of baseline levels and covariates, relative to patients randomized to the usual care control condition.
研究概览
研究类型
介入性
注册 (实际的)
50
阶段
- 第三阶段
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Quebec
-
Montreal、Quebec、加拿大、H4J 1C5
- Hôpital du Sacré-Cœur de Montréal
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 及以上 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- Patients 18 years and older
- Primary diagnosis of moderate-severe persistent asthma (as per GINA)
- Prescribed inhaled corticosteroid medication (min dose of 250 µg fluticasone equivalent per day) for at least 12 consecutive months
- Uncontrolled asthma (≤ 19 on the Asthma Control Test)
- Covered by a drug insurance plan (e.g., RAMQ)
- Non-adherent to ICS medication (based on having filled less than 30% of their prescriptions over the last year)
- Able to speak English or French.
Exclusion Criteria:
- Any other medical condition that confers greater illness morbidity than asthma (e.g., active cancer)
- Severe psychopathology (e.g., schizophrenia)
- Apparent cognitive or language deficit
- Are or plan to become pregnant or move outside of Quebec over the course of the study.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
安慰剂比较:Usual care
Standard medical care within 4-6 week period
|
Standard medical care within 4-6 week period
|
|
实验性的:Motivational interviewing
Brief MI sessions within 4-6 week period
|
Brief MI 3x30 minute sessions within 4-6 week period
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Inhaled corticosteroid adherence
大体时间:12 months post-intervention
|
measured according to the following validated equation: # of treatment days (based on the # of canisters filled at the pharmacy x the duration of each prescription) divided by the # of prescription days (# of days the patient is expected to be taking his/her medication)
|
12 months post-intervention
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Inhaled corticosteroid adherence
大体时间:6 months post-intervention
|
measured according to the following validated equation: # of treatment days (based on the # of canisters filled at the pharmacy x the duration of each prescription) divided by the # of prescription days (# of days the patient is expected to be taking his/her medication)
|
6 months post-intervention
|
|
Asthma Control Questionnaire (Juniper)
大体时间:12 months post-intervention, with preliminary data collected at 6 months
|
12 months post-intervention, with preliminary data collected at 6 months
|
|
|
Asthma Control Test
大体时间:12 months post-intervention, with preliminary data collected at 6 months
|
12 months post-intervention, with preliminary data collected at 6 months
|
|
|
Asthma Self-Efficacy Scale (Tobin)
大体时间:12 months post-intervention, with preliminary data collected at 6 months
|
12 months post-intervention, with preliminary data collected at 6 months
|
|
|
Asthma Quality of Life Questionnaire (Juniper)
大体时间:12 months post-intervention, with preliminary data collected at 6 months
|
12 months post-intervention, with preliminary data collected at 6 months
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2008年6月1日
初级完成 (实际的)
2013年3月1日
研究完成 (实际的)
2013年3月1日
研究注册日期
首次提交
2010年5月27日
首先提交符合 QC 标准的
2010年5月27日
首次发布 (估计)
2010年5月28日
研究记录更新
最后更新发布 (实际的)
2018年2月13日
上次提交的符合 QC 标准的更新
2018年2月9日
最后验证
2015年7月1日
更多信息
与本研究相关的术语
其他研究编号
- MBMC001
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.